S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20

Acer Therapeutics Stock Forecast, Price & News

-0.06 (-2.65%)
(As of 11/26/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
28,530 shs
Average Volume
557,208 shs
Market Capitalization
$31.48 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive ACER News and Ratings via Email

Sign-up to receive the latest news and ratings for Acer Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Acer Therapeutics logo

About Acer Therapeutics

Acer Therapeutics, Inc. is a pharmaceutical company. It engages in the acquisition, development and commercialization of therapies for medical needs. Its product pipeline includes ACER-001 Edsivo and ACER-2820. The Edsivo is a type of celiprolol for Vascular Ehlers-Danlos syndrome. The ACER-001 is for the treatment of urea cycle disorders and Maple Syrup Urine diseases. The company was founded on March 15, 1991 and is headquartered in Newton, MA.


Relief Reports that its U.S. Collaboration...
November 12, 2021 |  benzinga.com
Acer's (ACER) NDA for ACER-001 in UCD Gets FDA Acceptance
October 7, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
Book Value
$0.15 per share


Net Income
$-22.89 million
Pretax Margin




Free Float
Market Cap
$31.48 million
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

1.10 out of 5 stars

Medical Sector

1221st out of 1,391 stocks

Pharmaceutical Preparations Industry

583rd out of 669 stocks

Analyst Opinion: 0.0Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -

Acer Therapeutics (NASDAQ:ACER) Frequently Asked Questions

Is Acer Therapeutics a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Acer Therapeutics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Acer Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ACER, but not buy additional shares or sell existing shares.
View analyst ratings for Acer Therapeutics
or view top-rated stocks.

How has Acer Therapeutics' stock been impacted by Coronavirus?

Acer Therapeutics' stock was trading at $3.38 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ACER stock has decreased by 34.9% and is now trading at $2.20.
View which stocks have been most impacted by COVID-19

Are investors shorting Acer Therapeutics?

Acer Therapeutics saw a increase in short interest in October. As of October 15th, there was short interest totaling 353,700 shares, an increase of 139.1% from the September 30th total of 147,900 shares. Based on an average trading volume of 437,400 shares, the days-to-cover ratio is currently 0.8 days. Currently, 2.9% of the shares of the stock are short sold.
View Acer Therapeutics' Short Interest

When is Acer Therapeutics' next earnings date?

Acer Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, March 7th 2022.
View our earnings forecast for Acer Therapeutics

How were Acer Therapeutics' earnings last quarter?

Acer Therapeutics Inc. (NASDAQ:ACER) posted its quarterly earnings data on Friday, November, 19th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.28) by $0.05.
View Acer Therapeutics' earnings history

Who are Acer Therapeutics' key executives?

Acer Therapeutics' management team includes the following people:
  • Christopher Schelling, President, Chief Executive Officer & Director
  • Harry S. Palmin, Chief Operating & Financial Officer
  • Stacey Bain, Vice President-Clinical Operations
  • John M. Klopp, Chief Technology Officer
  • Matthew T. Seibt, Chief Commercial Officer

What is Jason Chen's approval rating as Acer Therapeutics' CEO?

64 employees have rated Acer Therapeutics CEO Jason Chen on Glassdoor.com. Jason Chen has an approval rating of 99% among Acer Therapeutics' employees. This puts Jason Chen in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Acer Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Acer Therapeutics investors own include Novavax (NVAX), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Sarepta Therapeutics (SRPT), Advanced Micro Devices (AMD), Amarin (AMRN), VBI Vaccines (VBIV), NVIDIA (NVDA), Idera Pharmaceuticals (IDRA) and Inovio Pharmaceuticals (INO).

What is Acer Therapeutics' stock symbol?

Acer Therapeutics trades on the NASDAQ under the ticker symbol "ACER."

Who are Acer Therapeutics' major shareholders?

Acer Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Geode Capital Management LLC (0.45%), Citadel Advisors LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Company insiders that own Acer Therapeutics stock include Chris Schelling, Donald Joseph and Steve Aselage.
View institutional ownership trends for Acer Therapeutics

Which institutional investors are buying Acer Therapeutics stock?

ACER stock was bought by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, and Citadel Advisors LLC. Company insiders that have bought Acer Therapeutics stock in the last two years include Chris Schelling, Donald Joseph, and Steve Aselage.
View insider buying and selling activity for Acer Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Acer Therapeutics?

Shares of ACER can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Acer Therapeutics' stock price today?

One share of ACER stock can currently be purchased for approximately $2.20.

How much money does Acer Therapeutics make?

Acer Therapeutics has a market capitalization of $31.48 million. The biopharmaceutical company earns $-22.89 million in net income (profit) each year or ($1.07) on an earnings per share basis.

How many employees does Acer Therapeutics have?

Acer Therapeutics employs 2,018 workers across the globe.

What is Acer Therapeutics' official website?

The official website for Acer Therapeutics is www.acertx.com.

Where are Acer Therapeutics' headquarters?

Acer Therapeutics is headquartered at 300 WASHINGTON STREET SUITE 351, NEWTON MA, 02458.

How can I contact Acer Therapeutics?

Acer Therapeutics' mailing address is 300 WASHINGTON STREET SUITE 351, NEWTON MA, 02458. The biopharmaceutical company can be reached via phone at (844) 902-6100, via email at [email protected], or via fax at 281-872-8585.

This page was last updated on 11/27/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.